Opus Genetics' OPGx-BEST1 improves retinal sensitivity in 75% of evaluable patients in early-stage trial
IRD•Opus Genetics said OPGx-BEST1 improved retinal sensitivity in 75% of evaluable patients in an early-stage trial. The company also reported OPGx-LCA5 vision improvements through 24 months in adults and expects dosing to begin in its fully enrolled Phase 3 trial in the fourth quarter of 2026.
1. Gene therapy trial results
Opus Genetics presented results for its OPGx-LCA5 and OPGx-BEST1 gene therapies at Retina in Rio 2026. OPGx-BEST1 improved retinal sensitivity in 75% of evaluable low-dose participants, and the Phase 1/2 trial completed high-dose cohort enrollment with 11 participants.
2. OPGx-LCA5 development
Adults treated with OPGx-LCA5 showed sustained vision improvements through 24 months, while pediatric results were encouraging through six months. The fully enrolled Phase 3 trial is expected to begin dosing in the fourth quarter of 2026.
